Photodynamic Priming and Minocycline Overcome Chemoresistance by Reprogramming the Pancreatic Tumor Immune Microenvironment In Vivo
Advanced Science · 2026-07 · 13 (38)
DOI: 10.1002/advs.75291 ↗At a glance
Journal article in Advanced Science, published online on 2026-04-17. Written by Fernanda V Cabral and 7 co-authors. Institution: Wellman Center For Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. Major MEDLINE topics: Tumor Microenvironment, Pancreatic Neoplasms, Minocycline, Drug Resistance, Neoplasm. Cited 1 times so far (Crossref); 60 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIBIB NIH HHS, NIH HHS, NCI NIH HHS.
Abstract (original language)
Overcoming drug resistance in pancreatic ductal adenocarcinoma (PDAC) remains a major challenge due to dense fibrotic stroma, DNA repair–mediated resistance, drug efflux mechanisms, and an immunosuppressive tumor microenvironment (TME). Here, we use photoactivatable multi‐inhibitor liposomes (PMILs) as a clinically translatable strategy to immunomodulate and enhance PDAC treatment using FDA‐approved agents: minocycline for tumor priming by downregulating Tdp1, benzoporphyrin derivative incorporated into the liposomal bilayer for photodynamic priming (PDP) of the microenvironment, and irinotecan (IRI) for cytotoxicity. PMILs enable light‐triggered PDP followed by IRI release. The reduced Tdp1 combined with PDP and IRI acts synergistically to enhance antitumor activity. In an orthotopic PDAC mouse model, dual priming significantly increased intratumoral IRI accumulation while downregulating Tdp1 and ABCG2, two key mediators of IRI resistance. These effects were augmented by immune activation, including increased CD8 + T‐cell infiltration, reduced regulatory T cells, and M2‐like macrophage population. This combination achieved sustained local tumor regression, abscopal effects in untreated distant tumors, and a significant improvement in long‐term survival (63%). By integrating clinically approved agents with non‐overlapping mechanisms within a light‐activated delivery platform, this approach enhances IRI efficacy, reprograms the TME, and promotes antitumor immunity, offering a translatable strategy to sensitize PDAC to chemo‐ and immunotherapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Wellman Center For Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Department of Bioengineering, University of Texas at Dallas, Richardson, Texas, USA.
- Fischell Department of Bioengineering, College Park, University of Maryland, Maryland, MD, USA.
- Division of Health Sciences and Technology, Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
ORCID profiles: Fernanda V Cabral, Girgis Obaid, Huang-Chiao Huang, Tayyaba Hasan
Funding
- NIBIB NIH HHS
- NIH HHS
- NCI NIH HHS
- National Science Foundation
Cite
APA
Cabral, F. V., Quilez-Alburquerque, J., Mooradian, O., Vytheswarran, S., Parshad, B., Obaid, G., Huang, H. C., & Hasan, T. (2026). Photodynamic Priming and Minocycline Overcome Chemoresistance by Reprogramming the Pancreatic Tumor Immune Microenvironment In Vivo. Advanced Science, 13(38). https://doi.org/10.1002/advs.75291
Vancouver
Cabral FV, Quilez-Alburquerque J, Mooradian O, Vytheswarran S, Parshad B, Obaid G, et al. Photodynamic Priming and Minocycline Overcome Chemoresistance by Reprogramming the Pancreatic Tumor Immune Microenvironment In Vivo. Advanced Science. 2026;13(38). doi:10.1002/advs.75291
BibTeX
@article{Cabral2026,
author = {Cabral, Fernanda V and Quilez-Alburquerque, Jose and Mooradian, Olivia and Vytheswarran, Shivendran and Parshad, Badri and Obaid, Girgis and Huang, Huang-Chiao and Hasan, Tayyaba},
title = {Photodynamic Priming and Minocycline Overcome Chemoresistance by Reprogramming the Pancreatic Tumor Immune Microenvironment In Vivo},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {38},
doi = {10.1002/advs.75291}
}
EUVIMED